Laura Stampleman

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra et al. · The Lancet Haematology · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Chia‐Jen Liu, Noopur Raje et al. · Clinical Cancer Research · 2018 · 42 citations · Full text

Medicine, Oncology, Pharmacology +16